Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin
March 8, 2023BOSTON, March 8, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to prevent and treat infectious diseases and cancer, today announced the appointment of three highly accomplished biopharma executives to its board of directors: Paul Wotton, Ph.D.; Robert R. Ruffolo Jr., Ph.D.; and Kevin F. McLaughlin, MBA.